Alternatives to Germany – Pharmaceutical products – Arzneimittelrabattverträge gem. § 130a Abs. 8 SGB V im Rahmen von Open-House-Verfahren

Germany – Pharmaceutical products – 61. Generika-Ausschreibung

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Irbesartan und Hydrochlorothiazid (ATC: C09DA24)

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Entecavir (ATC: J05AF10 - in der Darreichungsform Filmtabletten)

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach §130a Abs.8 SGB V zu verschiedenen Wirkstoff-/en/-kombinationen mit jederzeitiger Abschlussmöglichkeit im Rahmen des sog. Open House-Verfahrens

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Vilanterol und Umeclidiniumbromid (ATC: R03AL03)

Expected Outcome: the proposals under this call are expected to address one or more of the following subjects : • Enhanced personalized monitoring, care and treatments, focusing on the development of highly customized healthcare solutions, including the required research and diagnostic tools, tailored to individual needs, covering various scenarios such as chronic disease management, physiotherapy, precision diagnosis, personalized medicine/treatment, pre- and postoperative care, and daily assistance in homes and common spaces. It also targets effective management of chronic diseases and elderly care through personalized monitoring and interventions facilitated by advanced sensor technologies and edge-to-cloud solutions. This includes the development and integration of solutions for Hospitalization at Home, enabling patients to receive complex, remotely supervised care using intelligent medical devices capable of sensing, analysing, and transmitting real-time data. This requires a continuum, from in-hospital diagnostics to robust, long-term patient support at home via AI-driven care pathways and hospitalization at home. • Prevention and treatment of diseases, allowing the improved…

Expected Outcome: Successful proposals will contribute to the implementation of the EU initiative on Biotechnology and Biomanufacturing and the EU Life Sciences Strategy as well as the updated EU Bioeconomy Strategy, the upcoming EU Biotechnology Act and EU Circular Economy Act. Projects’ results are expected to contribute to the following expected outcomes: Full industrial scale biorefinery and related value chain(s) for the production of nutritional food ingredients. Resilience and strategic autonomy of EU food sectors via diversification of nutritional food ingredient sources. Increased environmental sustainability of food sectors (e.g. addressing issues like land use, water use, energy consumption, nitrogen cycle, other nutrients, etc.). Improved consumers awareness and acceptance of nutritional food ingredients from alternative sources, contributing to sustainable healthy diets. Scope: Human nutrition is a key area where the bio-based industries can play an important role in addressing the present societal and climate challenges. Considerable attention is given to the utilisation of alternative sources of proteins, fibres and oils/fats, due to the increasing world population…

Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: The EU is reinforced as an internationally recognised driver of research and innovation in Rare Diseases (RD) and thereby substantially contributing to the achievement of the Sustainable Development Goals related to rare diseases. Research funders align, adopt and implement their RD research policies allowing for the optimal generation and translation of knowledge into meaningful health products and interventions responding to the needs of people living with a rare disease across Europe and globally. The RD research community at large benefit from and use an improved comprehensive knowledge framework and cross-border FAIR [1] data access and analysis, including rare diseases registries, by integrating the EU, national/regional data and information infrastructures to improve translational research. People living with a rare…

Expected Outcome: Project results are expected to contribute to all the following expected outcomes: Advance in the achievement of the Strategic Energy Technology (SET) Plan’s research and innovation priorities and targets for wind energy; Efficient and effective support to wind energy research and innovation through alignment and cooperation among different actors, avoiding fragmentation of efforts; Energy producers and consumers benefit from increased performance of wind energy technologies with the focus on efficiency and flexibility, reduced cost, improved reliability and sustainability, operation and maintenance, safety, robustness and security during all stages of the lifetime of a wind energy farm from installation, operation and maintenance to decommissioning; Increased contribution of wind energy to the energy system, with minimal impacts on health and the environment (notably biodiversity and pollution) and at the lowest possible cost. Scope: The action contributes to address the Strategic Energy Technology (SET) Plan’s research and innovation priorities and targets for wind energy, as defined by the Implementation Working Group (IWG) on wind energy, the European…

Expected Outcome: Successful proposals will contribute to the updated EU Bioeconomy Strategy, Farm to Fork Strategy, the Horizon Europe Mission ‘A Soil Deal for Europe’, in particular the objectives: ‘Reduce soil pollution and enhance restoration’, the European Chemical Industry Action Plan as well as the Clean Industrial Deal. Projects results are expected to contribute to the following expected outcomes: Full industrial scale biorefinery and related value chain(s) for the sustainable production of bio-based fertilisers and/or crop protection solutions. Increased availability of cost-competitive and SSbD bio-based alternatives for fertilising and/or crop protection products with suitable agronomic efficacy. Reduced reliance on synthetic/mineral agricultural chemical products. Increased EU strategic autonomy, resilience and competitiveness through a robust cooperation among bio-based industries and farmers. Increased soil health, including minimising accumulation of microplastics and pollutants in soil and water, with positive effects on quality, security and resilience of food production in agriculture. Scope: FAO estimates that up to 40% of food crops are lost due to plant pests…

Expected Outcome: this topic is a continuation of the co-funded European partnership for research into radiation protection and detection of ionising radiation (PIANOFORTE) and constitutes the EU’s contribution for 2026-2027. The establishment of the partnership will contribute to the expected outcomes specified in topic HORIZON-EURATOM-2021-NRT-01-09. The partnership is expected to contribute to all of the following outcomes: establishing improved risk estimates for the justification of practices and optimisation of radiological protection of members of the public, patients, workers and the environment in all exposure situations (medical, natural, occupational and accidental – including co‑exposure and overlapping risks) to support the implementation of the Basic Safety Standards Directive; advancing state-of-the-art understanding of the link between exposure characteristics (radiation quality, dose, dose-rate and dose effects versus gravity) and cancer and non-cancer effects (including optimised detection and dosimetry); developing a knowledge base and analytical tools for the major features of variability in radiation response (including tissue reactions, cancers and cellular…

Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to the following expected outcomes: Through the European Cancer Patient Digital Centre (ECPDC), adolescent and young cancer patients and survivors as well as their caregivers have access to innovative tools and approaches to strengthen their mental health; Healthcare professionals have access to innovative tools to monitor and support the mental health of cancer patients and survivors as well as their caregivers Researchers and healthcare professionals have access and use reliable patient reported data to better understand the mental health needs of cancer patients and survivors and provide effective care. Scope: As part of its citizens engagement activities, the EU Cancer Mission has launched a dialogue with young cancer survivors, to better understand the specific needs and challenges faced during and after treatment. Mental health has been systematically highlighted as a major concern, stressing the importance of access to quality psychosocial support including through virtual, digital means along the different stages of the patient’s journey, at…